MIRA · MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals Inc (MIRA)
What's happening
- MIRA is up 2.02% today, trading at $0.65. — Live quote
- Volume today (113) is well below its 3-month average of 439,300. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 21 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $39.1M | $40.6M | $1.3M | $20.4M | $16.1M |
| P/E | -7.76 | -7.24 | -0.20 | -2.89 | -2.22 |
| Price/Book | 4.79 | 4.35 | 0.17 | 35.83 | 12.40 |
| ROE | -61.67% | -60.00% | -86.14% | -1238.32% | -559.18% |
| ROA | -61.37% | -59.27% | -85.19% | -812.68% | -516.79% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-09-17; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -56.9%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on MIRA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Net income | -$1.2M | -$1.2M | -$1.1M | -$1.5M | -$1.8M | -$2.0M | -$1.7M | -$1.7M |
| EPS (diluted) | $-0.03 | $-0.03 | $-1.18 | $-0.09 | $-0.11 | $-0.14 | $-0.11 | $-0.15 |
| EPS (basic) | $-0.03 | $-0.03 | $-1.18 | $-0.09 | $-0.11 | $-0.14 | $-0.11 | $-0.15 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $8.2M | $9.5M | $11.1M | $7.6M | $868.3K | $1.4M | $2.9M | $4.3M |
| Total liabilities | $40.8K | $114.8K | $702.1K | $83.9K | $298.5K | $106.2K | $723.3K | $692.8K |
| Stockholders' equity | $8.2M | $9.3M | $10.4M | $7.5M | $569.9K | $1.3M | $2.2M | $3.6M |
| Total current assets | $8.2M | $9.4M | $11.1M | $7.6M | $832.9K | $1.4M | $2.9M | $4.2M |
| Total current liabilities | $40.8K | $114.8K | $702.1K | $83.9K | $298.5K | $106.2K | $723.3K | $692.8K |
| Cash & equivalents | $3.6M | $4.8M | $6.3M | $2.6M | $730.5K | $1.2M | $2.8M | — |
| Marketable securities (current) | $4.5M | $4.6M | $4.7M | $4.9M | — | — | — | — |
| Accounts payable | $40.8K | $34.0K | $129.2K | $83.9K | $298.5K | $100.7K | $723.3K | — |
| Accrued liabilities | — | — | — | — | — | $5.5K | $300.0K | — |
| Other current liabilities | — | — | $572.9K | — | — | — | — | — |
| Common stock & paid-in capital | $4.2K | $4.2K | $4.2K | $4.0K | $1.7K | $1.7K | $1.7K | $1.6K |
| Retained earnings | -$41.9M | -$40.7M | -$39.6M | -$33.6M | -$32.5M | -$30.9M | -$29.1M | -$26.7M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.2M | -$1.2M | -$1.1M | -$1.1M | -$799.7K | -$1.6M | -$1.8M | -$1.8M |
| Financing cash flow | $0 | -$330.6K | $4.8M | $3.0M | $323.8K | $3.4K | $493.4K | $3.2M |
| Share-based compensation | $21.9K | $107.6K | $4.6M | $390.8K | $489.6K | $874.8K | $546.8K | $269.0K |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Net income | -$10.4M | -$7.9M | -$12.0M | -$7.1M |
| EPS (diluted) | $-1.35 | $-0.51 | $-0.85 | $-0.40 |
| EPS (basic) | $-1.35 | $-0.51 | $-0.85 | $-0.40 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Total assets | $11.1M | $2.9M | $4.9M | $858.1K |
| Total liabilities | $702.1K | $723.3K | $558.1K | $1.5M |
| Stockholders' equity | $10.4M | $2.2M | $4.4M | -$596.2K |
| Total current assets | $11.1M | $2.9M | $4.9M | $494.4K |
| Total current liabilities | $702.1K | $723.3K | $558.1K | $1.4M |
| Cash & equivalents | $6.3M | $2.8M | — | — |
| Marketable securities (current) | $4.7M | — | — | — |
| Accounts payable | $129.2K | $723.3K | — | — |
| Other current liabilities | $572.9K | — | — | — |
| Common stock & paid-in capital | $4.2K | $1.7K | $1.5K | $6.7K |
| Retained earnings | -$39.6M | -$29.1M | -$21.3M | -$9.3M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Operating cash flow | -$4.7M | -$5.6M | -$4.5M | -$5.6M |
| Financing cash flow | $8.2M | $3.8M | $8.8M | $3.1M |
| Share-based compensation | $6.3M | $1.9M | $2.6M | $1.3M |
| Change in accounts receivable | — | — | $11.9K | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding MIRA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2024-05-21 to 2025-10-01
Recent transactions
- Most recent: Shekhat Denil Nanji (Director) — Grant / award of 22,378 shares on 2025-10-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Shekhat Denil Nanji | Director | Grant / award | 2025-10-01 | 22,378 |
| Aminov Erez | Chief Executive Officer | Grant / award | 2025-10-01 | 2,685,456 |
| McNulty Brian Patrick | 10% owner | Open market sale | 2024-08-28 | 200,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-10-01 | Shekhat Denil Nanji | Director | Grant / award | 22,378 | $1.35 |
| 2025-10-01 | Aminov Erez | Chief Executive Officer | Grant / award | 2,685,456 | — |
| 2025-08-29 | Aminov Erez | Chief Executive Officer | Grant / award | 62,500 | $1.37 |
| 2024-11-20 | Aminov Erez | Chief Executive Officer | Open market sale | 44,590 | $1.27 |
| 2024-11-19 | Aminov Erez | Chief Executive Officer | Open market sale | 55,410 | $1.39 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 22:58 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-17 | 8-K | 2026-09-17 | View on SEC.gov → |
| 2026-09-16 | 8-K | 2026-09-11 | View on SEC.gov → |
| 2026-09-01 | 8-K | 2026-09-01 | View on SEC.gov → |
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-31 | 8-K | 2026-07-27 | View on SEC.gov → |
| 2026-07-10 | 8-K | 2026-07-10 | View on SEC.gov → |
| 2026-07-06 | 8-K | 2026-07-06 | View on SEC.gov → |
| 2026-06-25 | 8-K | 2026-06-25 | View on SEC.gov → |
| 2026-06-17 | 8-K | 2026-06-17 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-12 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-12 | View on SEC.gov → |
Recent news
Headlines about MIRA (MIRA Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.
-
Modera Launches AI-Powered Platform Mira to Support Tailored Financial Advice for Clients
Yahoo Finance · 2026-10-21 -
Mira-Bhayandar 10% Water Cut: MBMC Releases Weekly Shutdown Timings
Mumbai Live · 2026-10-21 -
Mira-Bhayander Water Crisis: Supply To Remain Affected For Fixed Period Every Week; Check Details
NDTV Profit · 2026-10-21 -
Mumbai Metro Line 9 Phase II Expected To Open In December, Four New Stations To Boost Mira-Bhayandar...
Lokmat Times · 2026-10-21 -
A 100-Inch Screen from Just 19cm Away: XGIMI 'MIRA Pro'
Inven Global · 2026-10-21 -
From Kashigaon to Mira-Bhayandar: Mumbai Metro Line 9’s second phase likely to be ready by December
The Times of India · 2026-10-20 -
A lease is signed for CoMira’s planned Saudi facility to make diagnostic tests.
Stock Titan · 2026-10-20 -
Mira-Bhayandar Water Cut Brings Weekly Supply Shutdowns
Urban Acres · 2026-10-20
No headlines in this category right now — try “All”.